Literature DB >> 19841577

Mutation analysis in primary immunodeficiency diseases: case studies.

Amy P Hsu1, Thomas A Fleisher, Julie E Niemela.   

Abstract

PURPOSE OF REVIEW: The application of mutation analysis is becoming an integral part of the complete evaluation of patients with primary immunodeficiencies, and as such, clinicians caring for these patients must develop a better understanding of the utility and challenges of this important laboratory technology. RECENT
FINDINGS: Genomic DNA sequencing is currently the standard approach used to characterize a possible gene mutation causing a specific primary immunodeficiency. There are clinical situations in which this approach is revealing of a genetic defect and other circumstances in which this generates a false-positive or false-negative result. One case study is presented that reviews a straightforward analysis that clarifies the genetic basis of a primary immunodeficiency, and four cases are presented that required additional studies to clarify the underlying basis of the immunodeficiency. In the latter circumstances, the rationale for additional studies is outlined and the outcome of these is presented.
SUMMARY: The identification of a gene mutation as the underlying basis of a primary immunodeficiency begins with the evaluation of the clinical presentation focusing on the infection history so as to develop a differential diagnosis including potential genetic causes. The next step is to obtain specific laboratory studies, including immunologic function evaluation, and, based on these findings, to proceed with DNA sequencing of one or several selected candidate genes. Genomic DNA sequencing has certain limitations, and alternative follow-up approaches may be necessary to establish the molecular basis of the primary immunodeficiency in a given patient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841577      PMCID: PMC2774237          DOI: 10.1097/ACI.0b013e3283328f59

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  37 in total

1.  Genetic diagnosis in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls.

Authors:  H Lohi; J Turnbull; X C Zhao; S Pullenayegum; L Ianzano; M Yahyaoui; M A Mikati; N P Quinn; S Franceschetti; F Zara; B A Minassian
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

2.  Classification of mutations in the human CD40 ligand, gp39, that are associated with X-linked hyper IgM syndrome.

Authors:  J Bajorath; K Seyama; S Nonoyama; H D Ochs; A Aruffo
Journal:  Protein Sci       Date:  1996-03       Impact factor: 6.725

3.  A "silent" polymorphism in the MDR1 gene changes substrate specificity.

Authors:  Chava Kimchi-Sarfaty; Jung Mi Oh; In-Wha Kim; Zuben E Sauna; Anna Maria Calcagno; Suresh V Ambudkar; Michael M Gottesman
Journal:  Science       Date:  2006-12-21       Impact factor: 47.728

4.  The structural basis of hyper IgM deficiency - CD40L mutations.

Authors:  J Thusberg; M Vihinen
Journal:  Protein Eng Des Sel       Date:  2007-02-16       Impact factor: 1.650

5.  A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.

Authors:  Ryan L Davis; Vivienne M Homer; Peter M George; Stephen O Brennan
Journal:  Hum Mutat       Date:  2009-02       Impact factor: 4.878

6.  A novel point mutation in the CYBB gene promoter leading to a rare X minus chronic granulomatous disease variant--impact on the microbicidal activity of neutrophils.

Authors:  Federica Defendi; Eva Decleva; Cécile Martel; Pietro Dri; Marie José Stasia
Journal:  Biochim Biophys Acta       Date:  2009-03

7.  Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity.

Authors:  Eric P Hanson; Linda Monaco-Shawver; Laura A Solt; Lisa A Madge; Pinaki P Banerjee; Michael J May; Jordan S Orange
Journal:  J Allergy Clin Immunol       Date:  2008-10-11       Impact factor: 10.793

8.  An FBN1 pseudoexon mutation in a patient with Marfan syndrome: confirmation of cryptic mutations leading to disease.

Authors:  Dong-Chuan Guo; Prateek Gupta; Van Tran-Fadulu; Tera V Guidry; Magalie S Leduc; Frederick V Schaefer; Dianna M Milewicz
Journal:  J Hum Genet       Date:  2008-09-17       Impact factor: 3.172

Review 9.  Diagnostics of pathogenic splicing mutations: does bioinformatics cover all bases?

Authors:  Linda Hartmann; Stephan Theiss; Dieter Niederacher; Heiner Schaal
Journal:  Front Biosci       Date:  2008-05-01

10.  The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis.

Authors:  Thomas A Fleisher
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

View more
  5 in total

Review 1.  Molecular- and flow cytometry-based diagnosis of primary immunodeficiency disorders.

Authors:  Joao B Oliveira; Thomas A Fleisher
Journal:  Curr Allergy Asthma Rep       Date:  2010-11       Impact factor: 4.806

Review 2.  Novel sequencing-based strategies for high-throughput discovery of genetic mutations underlying inherited antibody deficiency disorders.

Authors:  Hong-Ying Wang; Ashish Jain
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

3.  Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficiencies.

Authors:  Roshini S Abraham
Journal:  Clin Mol Allergy       Date:  2011-04-09

Review 4.  Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders.

Authors:  Jamie Nourse; Stefano Spada; Sven Danckwardt
Journal:  Biomolecules       Date:  2020-06-17

5.  Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome.

Authors:  Eleonora Gambineri; Sara Ciullini Mannurita; David Hagin; Marina Vignoli; Stephanie Anover-Sombke; Stacey DeBoer; Gesmar R S Segundo; Eric J Allenspach; Claudio Favre; Hans D Ochs; Troy R Torgerson
Journal:  Front Immunol       Date:  2018-11-01       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.